Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$957K Sell
8,594
-14,515
-63% -$1.72M ﹤0.01% 2117
2025
Q4
$3.12M Buy
+23,109
New +$2.52M 0.01% 1506
2025
Q2
Sell
-220,845
Closed -$1.38M 4432
2025
Q1
$1.38M Sell
220,845
-81,797
-27% -$554K 0.01% 1723
2024
Q4
$2.22M Buy
302,642
+45,225
+18% +$416K 0.01% 1699
2024
Q3
$2.97M Buy
257,417
+80,807
+46% +$968K 0.01% 1596
2024
Q2
$2.33M Sell
176,610
-10,434
-6% -$149K ﹤0.01% 1959
2024
Q1
$2.67M Buy
+187,044
New +$2.41M ﹤0.01% 1779

Other funds holding ABVX

Walleye Capital's ABVX Position: Q1 2026 in Review

Walleye Capital reduced its Abivax (ABVX) stake by 63% in Q1 2026, selling an estimated $1.72M and leaving 8,594 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Walleye Capital first reported a position in ABVX in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.12M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Walleye Capital held 8,594 shares of Abivax worth $957K as of Q1 2026.
  • Walleye Capital sold 14,515 Abivax shares in Q1 2026, an estimated $1.72M.
  • Abivax made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2117 holding.
  • Walleye Capital first reported a position in Abivax in Q1 2024 and has held it in 7 quarters since.
  • Walleye Capital's Abivax position peaked at $3.12M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.